Aeromonas hydrophila AHL 0905-2 and Streptococcus agalactiae N14G as Combined Vaccine Candidates for Nile Tilapia
Abstract
In Indonesia, the Nile tilapia (Oreochromis niloticus) is the most widely farmed and available fish for consumption. Production loss due to bacterial infection by Aeromonas hydrophila and Streptococcus agalactiae is the main problem in tilapia cultivation. This study aimed to determine the occurrence of concurrent infection of Aeromonas hydrophila AHL 0905-2 and Streptococcus agalactiae N14G in Nile tilapia based on biochemical and molecular characteristics. From the results of biochemical assay and sequence analysis of the 16S rRNA fragment, Aeromonas hydrophila and Streptococcus agalactiae were confirmed. Genes for aerolysin (417 bp), nuclease (504 bp), lipase (155 bp), and serine protease (211 bp) were found in Aeromonas hydrophila AHL 0905-2, while Streptococcus agalactiae N14G was determined as a 1b serotype group that had genes for CPS L (688 bp), CPSG (621 bp), and CPS J (272 bp). The confirmation in tilapia of Aeromonas hydrophila and Streptococcus agalactiae by PCR and sequencing is important for enabling the detection of these organisms and also for the development of a combined vaccine to tackle co-infection.
Downloads
Copyright (c) 2022 Nunak Nafiqoh, Hessy Novita, Desy Sugiani, Lila Gardenia, Taukhid Taukhid, Arynta Widyaningrum, Dine Resti Susanti

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
HAYATI J Biosci article's license is CC-BY-NC. This license lets others distribute, remix, tweak, and build upon author's work, as long as they credit the original creation.
Authors who submit and publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal/publisher non exclusive publishing rights with the work simultaneously licensed under a https://creativecommons.org/
licenses/by-nc/4.0/ Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. - Authors can still use their work commercially
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).